On January 22, 2024, Biodexa Pharmaceuticals Plc shared a letter from CEO Stephen Stamp outlining the company's progress for the fiscal year ending December 31, 2023, and providing a future outlook for 2024. The filing is significant for shareholders regarding the company's performance and direction.